{"id":43032,"date":"2014-01-11T21:16:03","date_gmt":"2014-01-12T02:16:03","guid":{"rendered":"http:\/\/1boringoldman.com\/?p=43032"},"modified":"2014-01-11T21:22:34","modified_gmt":"2014-01-12T02:22:34","slug":"totally-crazy","status":"publish","type":"post","link":"https:\/\/1boringoldman.com\/index.php\/2014\/01\/11\/totally-crazy\/","title":{"rendered":"totally crazy&#8230;"},"content":{"rendered":"<div align=\"justify\">I find it almost impossible to hold what this article talks about in my mind. &quot;<em><strong><font color=\"#200020\">Drug company sales representatives, using data these  companies supply,  can know before entering a doctor&#8217;s office if he or  she favors their  products or those of a competitor.<\/font><\/strong><\/em>&quot; The numbers are overwhelming:<\/div>\n<blockquote>\n<div align=\"center\" class=\"big\"><a target=\"_blank\" href=\"http:\/\/www.commondreams.org\/headline\/2014\/01\/10-8?\">Big Data + Big Pharma = Big Money<\/a><\/div>\n<div align=\"center\" class=\"big\"><strong><font color=\"#200020\">ProPublica<\/font><\/strong><\/div>\n<div align=\"center\" class=\"middle\">by Charles Ornstein<\/div>\n<div align=\"center\" class=\"small\">January 10, 2014<\/div>\n<p align=\"justify\">Need another reminder of how much drugmakers spend to discover what  doctors are prescribing? Look no further than new documents from the  leading keeper of such data. IMS Health Holdings Inc. says it pulled in nearly $2 billion in the first nine months of 2013, much of it from sweeping up data from pharmacies  and selling it to pharmaceutical and biotech companies. The firm&#8217;s  revenues in 2012 reached $2.4 billion, about 60 percent of it from  selling such information. The numbers became public because IMS, currently in private hands, recently filed to make a public stock offering. The company&#8217;s prospectus gives fresh insight into the huge dollars &ndash; and huge volumes of data &ndash; flowing through a little-watched industry. <\/p>\n<p align=\"justify\">IMS and its competitors are known as prescription drug information  intermediaries. Drug company sales representatives, using data these  companies supply, can know before entering a doctor&#8217;s office if he or  she favors their products or those of a competitor. The industry is  controversial, with some doctors and patient groups saying it threatens  the privacy of private medical information. The data maintained by the industry is huge. IMS, based in Danbury, Conn., says its collection includes  &quot;<strong><font color=\"#990000\">over 85 percent of the world&#8217;s prescriptions by sales revenue<\/font><\/strong>,&quot; as  well as <strong><font color=\"#990000\">comprehensive, anonymous medical records for 400 million  patients<\/font><\/strong>. All of this adds up to 10 petabytes worth of material &mdash; or about 10 million gigabytes, a figure roughly equal to all of the websites and online books, movies, music and TV shows that have been stored by the nonprofit Internet Archive.<\/p>\n<p align=\"justify\">IMS Health says it processes and brings order to more than 45 billion health care transactions  each year from more than 780,000 different feeds around the world. &quot;All  of the top 100 global pharmaceutical and biotechnology companies are  clients&quot; of its products, the firm&#8217;s prospectus says. Dr. Randall Stafford, a Stanford University professor who has used  IMS data for his research, said the company has grown markedly in recent  years through acquisitions of competitors and other companies that host  and analyze data. As the pharmaceutical industry has consolidated, he  says, IMS has evolved by offering more services and expanding in China  and India. &quot;They&#8217;ve been trying to beef up their competitiveness in some areas by making all of these acquisitions,&quot; he said.<\/p>\n<div align=\"justify\">IMS has especially expanded its database of anonymous patient  records, which can match patients&#8217; diagnoses with their prescriptions  and track changes over time, Stafford said. IMS sells two types of products:  information offerings and technology services. The information products  allow pharmaceutical companies to get national snapshots of prescribing  trends in more than 70 countries and data about individual prescribers  in 50 countries. IMS&#8217;s prospectus offers examples of the questions  companies are able to answer with its data, including which providers  generate the highest return on a sales rep&#8217;s visit, whether a rep drives  appropriate prescribing and how much reps should be paid&#8230;<\/div>\n<\/blockquote>\n<div align=\"justify\">I didn&#8217;t prescribe much and never saw drug reps, so this is a part of the world I sidestepped. But it immediately brings up a point I haven&#8217;t heard anyone mentioning. Apparently, a pharmaceutical company can find out exactly what I prescribe, and can come by anonymized patients records for their marketing research just by paying IMS&#8217; asking price. But they stand in front of us and act like our requests for the raw data from their clinical trials and for the subjects&#8217; anonymized clinical records is an affront to patient privacy and their commercial secrets. It&#8217;s hard for me to imagine that the pharmaceutical sales rep is privy to the data about my prescribing, and about my patients, but I&#8217;m unable see the data on the drug he&#8217;s\/she&#8217;s trying to get me to prescribe, except as it&#8217;s carefully abbreviated and dolled up for publication by his company&#8217;s medical writing team. It&#8217;s okay for marketing research, but not medical research? That is totally crazy&#8230; totally crazy&#8230;<\/div>\n","protected":false},"excerpt":{"rendered":"<p>I find it almost impossible to hold what this article talks about in my mind. &quot;Drug company sales representatives, using data these companies supply, can know before entering a doctor&#8217;s office if he or she favors their products or those of a competitor.&quot; The numbers are overwhelming: Big Data + Big Pharma = Big Money [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_bbp_topic_count":0,"_bbp_reply_count":0,"_bbp_total_topic_count":0,"_bbp_total_reply_count":0,"_bbp_voice_count":0,"_bbp_anonymous_reply_count":0,"_bbp_forum_subforum_count":0,"footnotes":""},"categories":[2],"tags":[],"class_list":["post-43032","post","type-post","status-publish","format-standard","hentry","category-politics"],"_links":{"self":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts\/43032","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/comments?post=43032"}],"version-history":[{"count":6,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts\/43032\/revisions"}],"predecessor-version":[{"id":43038,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts\/43032\/revisions\/43038"}],"wp:attachment":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/media?parent=43032"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/categories?post=43032"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/tags?post=43032"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}